NeoGenomics (NASDAQ:NEO) Price Target Raised to $19.00 at Needham & Company LLC

NeoGenomics (NASDAQ:NEO) had its price objective hoisted by Needham & Company LLC from $15.00 to $19.00 in a report issued on Wednesday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 41.79% from the company’s previous close.

Several other analysts have also recently issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Wall Street Zen upgraded NeoGenomics from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $12.00 to $25.00 in a research report on Wednesday, April 29th. Benchmark raised their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Finally, Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $15.14.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $13.40 on Wednesday. NeoGenomics has a 52 week low of $4.72 and a 52 week high of $15.57. The business has a fifty day simple moving average of $12.39 and a 200-day simple moving average of $10.65. The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41. The company has a market cap of $1.74 billion, a P/E ratio of -17.40 and a beta of 1.74.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The firm had revenue of $201.66 million for the quarter, compared to analysts’ expectations of $196.93 million. During the same quarter last year, the firm earned $0.03 earnings per share. The firm’s revenue for the quarter was up 11.2% compared to the same quarter last year. Equities research analysts forecast that NeoGenomics will post -0.15 EPS for the current year.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of NeoGenomics stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total value of $59,916.03. Following the transaction, the director directly owned 91,422 shares of the company’s stock, valued at $1,032,154.38. The trade was a 5.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEO. First Horizon Corp boosted its stake in shares of NeoGenomics by 52.6% in the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 865 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of NeoGenomics during the second quarter worth $32,000. Caitong International Asset Management Co. Ltd lifted its position in NeoGenomics by 110.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 1,556 shares during the period. Kestra Advisory Services LLC acquired a new position in NeoGenomics in the fourth quarter valued at approximately $39,000. Finally, GAMMA Investing LLC boosted its position in shares of NeoGenomics by 68.2% in the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock worth $42,000 after purchasing an additional 1,460 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

Trending Headlines about NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q2 earnings beat expectations: NeoGenomics reported adjusted earnings of $0.05 per share, compared with the $0.03 FactSet consensus estimate. Revenue reached $201.66 million, exceeding expectations of $196.93 million and increasing 11.2% year over year. NeoGenomics Q2 Earnings Snapshot
• Positive Sentiment: Full-year revenue outlook raised: Management forecast 2026 revenue of $802 million to $806 million, above the analyst consensus of approximately $800.3 million. The increased outlook reinforces the positive reaction to the quarterly results. NeoGenomics Reports Second Quarter 2026 Results
• Positive Sentiment: Results presentation highlighted operating momentum: The earnings materials and conference coverage focused on stronger profit and sales performance, with the company exceeding second-quarter expectations and improving its annual outlook. NeoGenomics 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Analyst consensus remains Hold: Despite the earnings beat and guidance increase, NeoGenomics continues to carry a consensus “Hold” rating, indicating that investors may want additional evidence of sustained profitability. NeoGenomics Receives Consensus Hold Rating
• Negative Sentiment: Profitability remains a concern: The company continues to report a negative net margin and negative return on equity, while analysts still expect a full-year loss, which could limit further upside if operating improvements do not continue.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.